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Abstract
Background: Hepatocellular carcinoma (HCC) is the most frequent primary invasive cancer of the liver. During the
last decade, the epidemiology of HCC has been continuously changing in developed countries, due to more
effective primary prevention and to successful treatment of virus-related liver diseases.
The study aims to examine survival by level of access to care in patients with HCC, for all patients combined and by age.
Methods: We included 2018 adult patients (15–99 years) diagnosed with a primary liver tumour, registered in the
Palermo Province Cancer Registry during 2006–2015, and followed-up to 30 October 2019. We obtained a proxy measure
of access to care by linking each record to the Hospital Discharge Records and the Ambulatory Discharge Records.
We estimated net survival up to 5 years after diagnosis by access to care (“easy access to care” versus “poor access to
care”), using the Pohar-Perme estimator. Estimates were age-standardised using International Cancer Survival Standard
(ICSS) weights. We also examined survival by access to care and age (15–64, 65–74 and≥ 75 years).
Results: Among the 2018 patients, 62.4% were morphologically verified and 37.6% clinically diagnosed. Morphologically
verified tumours were more frequent in patients aged 65–74 years (41.6%), while tumours diagnosed clinically were more
frequent in patients aged 75 years or over (50.2%). During 2006–2015, age-standardised net survival was higher among
HCC patients with “easy access to care” than in those with “poor access to care” (68% vs. 48% at 1 year, 29% vs. 11% at 5
years; p < 0.0001). Net survival up to 5 years was higher for patients with “easy access to care” in each age
group (p < 0.0001). Moreover, survival increased slightly for patients with easier access to care, while it
remained relatively stable for patients with poor access to care.
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Conclusions: During 2006–2015, 5-year survival was higher for HCC patients with easier access to care, probably
reflecting progressive improvement in the effectiveness of health care services offered to these patients.
Our linkage algorithm could provide valuable evidence to support healthcare decision-making in the context of the
evolving epidemiology of hepatocellular carcinoma.
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Background
Despite important diagnostic and therapeutic advances,
liver cancer remains highly lethal in both developing and
developed countries [1, 2]. Liver cancer is the fifth most
common cancer world-wide in men, the seventh in
women, and it is the second most common cause of
cancer death, with an estimated 782,000 new cases and
746,000 deaths per year [3].
Hepatocellular carcinoma (HCC) is the most frequent
primary invasive cancer of the liver, accounting for 60–
80% of all invasive malignancies of the liver [4, 5]. Its
development is closely related to the presence of chronic
liver disease with hepatitis B or C [6]. During the last
decade, the epidemiology of HCC has been continuously
changing in developed countries, due to more effective
primary prevention and to a successful treatment of
virus-related liver diseases, which highlighted the impact
of emerging risk factors, other than the well-documented
risk from excess alcohol consumption [7], and a conse-
quent shift to non-alcoholic fatty liver disease [8].
Population-based cancer registries have a quintessen-
tial role in generating real-world evidence on cancer in-
cidence, survival and the quality of cancer care [9–11].
Furthermore, registries are also challenged to develop
methods that can produce evidence on the real-world
impact of care pathways in support of healthcare
decision-makers [12, 13].
Population-based cancer survival trends provide re-
searchers and policy makers with evidence of the effective-
ness of control programmes, reflecting access to healthcare,
early diagnosis and optimal treatment [14]. The third cycle
of the CONCORD programme for global surveillance of
population-based cancer survival trends documented very
little improvement in age-standardised 5-year net survival
for liver cancer between 1995 and 1999 and 2010–2014, in
61 countries. Five-year survival was generally in the range
3–30% [1].
A more detailed analysis on patients diagnosed during
1995–2009 in 28 countries found a wide variation in 5-
year conditional survival (the probability of surviving up
to 5 years from diagnosis among patients who had
survived to the first anniversary of diagnosis) for hepato-
cellular carcinomas (25–52%). This partially reflects
variation in the proportion of patients diagnosed at an
advanced stage [15] whereas a poor prognosis for liver
cancer implies that most patients are diagnosed when
they are inoperable.
In 2010–2014, age-standardised 5-year net survival for
liver cancer was 20.3% (95%CI: 19.6–21.1) in Italy,
among the highest in the world, together with Korea,
Singapore, Taiwan and Belgium [1]. Moreover, about
90% of liver cancer in southern Italy is estimated to be
attributable to infection with hepatitis B virus (HBV) or
hepatitis C virus (HCV) [16]. Of interest, during the last
10 years in Italy, an improvement in HCC survival was
observed [17]. This is likely to be due both to improve-
ment in clinical surveillance and to the availability of
innovative drugs [5], thus leading to an evolution of the
aetiology and the epidemiological scenario of liver can-
cer, related to a progressive reduction of viral aetiology
and a consequent increase in the proportion of cases
due to non-viral causes [17].
Identification of pathways undertaken by patients diag-
nosed with cancer is an important issue to improve ac-
cess to care and, consequently, health outcomes such as
survival. Patients with poor access to health facilities
have lower survival, than those with easier access [18].
This study aims to investigate primary HCC survival
up to 5 years since diagnosis and to highlight any differ-
ence in survival by the level of access to care.
For this purpose, we analysed data on patients with
liver cancer, collected by the Palermo Province Cancer
Registry (PPCR), during 10 years of epidemiological
surveillance in an area with a population of 1,276,525 in-
habitants [19], characterised by the presence of 3 highly
specialised clinical centres for HCV treatment. We
applied a deterministic algorithm linkage to both morpho-
logically confirmed tumours and cancer diagnosed on the
basis of clinical investigation only, using all available
healthcare information sources.
Methods
We included 2018 adults (15–99 years) among residents
in the Palermo Province, who were diagnosed during
2006–2015 with a primary invasive liver neoplasm
(C22.0, behaviour code 3, in the International Classifica-
tion of Diseases for Oncology - ICD-O-3, Third Edition)
[20], registered in the Palermo Province Cancer Registry.
We excluded tumours arising from intrahepatic biliary
ducts (C22.1). We excluded from survival analysis 174
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(8.6%) patients who were diagnosed only from a death
certificate (DCO). We divided liver cancers into two
subgroups on the basis of morphology code [20] and
according to European Network of Cancer Registries
(ENCR) recommendations [21]: 1) malignant neoplasms
with a defined morphology, namely epithelial liver
tumours (ICD-O-3 codes 8170–8175; 8010; 8020; 8021;
8190; 8246; 8249); 2) malignant neoplasms with a
clinical-instrumental diagnosis (morphology code 8000,
behaviour code 3).
Linkage algorithm
We obtained a proxy measure of access to care through
the linkage algorithm showed in Fig. 1. We linked 2018
records to the Hospital Discharge Records (HDR), both
for ordinary and day-hospital admissions, to the Ambu-
latory Discharge Records (ADR) and the Pathological
Anatomy Reports (PAR). We performed a deterministic
linkage based on the tax code for every inpatient and
outpatient diagnosed with a primary invasive liver can-
cer. Assuming that a higher or lower number of contacts
with the healthcare service could be considered a proxy
for an easier or poorer access to healthcare, we explored
access to care, taking into account information derived
from different data flows: year of diagnosis, age at diag-
nosis, and number of HDR, ADR or PAR for every single
year of survival after diagnosis. More in depth, we
divided patients into two groups: patients linking with at
least two different healthcare sources, including PAR
(“easy access to care”), and patients linking with only an
HDR or ADR, but no PAR (“poor access to care”).
Patients diagnosed only through a death certificate
(DCO) were excluded from survival analysis.
Statistical analysis
We estimated net survival up to 5 years after diagnosis
for adults diagnosed during 2006–2015, and followed-up
to 30 October 2019, by access to care (“easy access to
care” versus “poor access to care”), with the non-
parametric Pohar-Perme estimator [22]. To estimate net
survival, we used life tables of all-cause mortality rates
by single year of age for Palermo Province for each cal-
endar year 2006–2018, provided by the Italian National
Statistics Institute (ISTAT) [19]. Estimates were age-
standardised using International Cancer Survival Stand-
ard (ICSS) weights [23] in which age at diagnosis is cate-
gorised into five age groups: 15–44, 45–54, 55–64, 65–
74, 75–99 years. Differences in survival between the two
categories of access to care were assessed using a log-
rank-type test [24]. We also examined differences in net
survival up to 5 years in primary liver cancer patients by
access to care and age (15–64, 65–74 and ≥ 75 years).
Fig. 1 Access to care linkage algorithm for patients with primary invasive liver neoplasms. Palermo Province Cancer Registry, 2006–2015. PPCR =
Palermo Province Cancer Registry; HDR = Hospital Discharge Records; ADR = Ambulatory Discharge Records; PAR = Pathological Anatomy Report;
DCO = Death Certificate Only; Y = yes, linked; N = not linked
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To analyse trends in 5-year survival, by ease of access
to care, we used the classical cohort approach for
patients diagnosed during 2006–2008 and 2009–2011
[25], all of whom had been followed up for at least 5
years, and the period approach for patients diagnosed in
2012–2015 [26].
Statistical analyses were performed by using the IDE
software RStudio (version 3.4.1 of 2017-06-30) for R
(version 2.1) [27, 28]. Net survival was estimated by
using “relsurv” and “periodR” packages [29, 30]. Two-
sided statistical significance of the difference between
paired survival estimates was set at 0.05.
Results
Among the 2018 adults with a primary invasive neo-
plasm of the liver (C22.0), diagnosed during 2006–2015,
1290 (63.9%) occurred in men and 728 (36.1%) in
women; 1259 (62.4%) were morphologically verified
(including histological or cytological confirmation) and
759 (37.6%) were diagnosed clinically (Table 1, Fig. 1).
The median follow-up time for the whole cohort was
1.5 years while the longest follow up was 13.0 years. Only
8 patients (0.4%) were lost to follow-up.
Epithelial liver tumours with a specified morphology
were more frequent in patients aged 65–74 years
(41.6%), followed by age-groups ≥75 (30.5%) and 15–64
(27.9%), while malignant neoplasm with a clinical or in-
strumental diagnosis were more frequent in patients
older than 75 years (50.2%), followed by 65–74 (30.0%)
and 15–64 (19.8%). Mean age at diagnosis was lower
among epithelial liver tumours with defined morphology
than those with a clinical or instrumental diagnosis (69
vs.73 years; p < 0.0001) (Table 1).
Among 2018 patients, 1259 (62.4%) patients with a
morphologically confirmed tumour linked to a PAR and
either a HDR or an ADR or both, with a median number
of 4 records linked for every single year of survival after
diagnosis, while among the remaining 759 patients
(37.6%), 585 were identified by at least one HDR or ADR,
but no PAR, with a median number of 1 record linked for
every single year of survival after diagnosis. Lastly, 174
patients (23%) were linked with a DCO (Fig. 1).
“Easy access to care” was more frequent in patients
with a morphologically confirmed liver tumour while
patients whose diagnosis was based solely on clinical
findings were more frequently characterised by “poor
access to care”.
During 2006–2015, age-standardised net survival was
substantially higher among primary invasive liver cancer
patients with “easy access to care” than in those with
“poor access to care” (68% vs. 48% at 1 year, 42% vs. 23%
at 3 years, 29% vs. 11% at 5 years; p < 0.0001; Fig. 2).
Survival up to 5 years was higher for patients with
“easy access to care” in each age group (p = < 0.0001)
(Fig. 3).
Survival increased slightly for patients with easier
access to care (2006–2008: 26.0, 95%CI 22.7–32.4%;
2009–2011: 30.3%, 24.8–36.0%; 2012–2015: 35.0%, 28.7–
41.3%), while it remained relatively stable for patients with
poor access to care (2006–2008: 11.8%, 8.2–17.0%; 2009–
2011: 11.9%, 8.4–17.7%; 2012–2015: 10.6%, 7.5–19.1%).
Discussion
Population-based cancer registries play a strategic role in
public health, producing continuous valuable information
for cancer control strategy and epidemiological surveillance
[31], although the informative potential of cancer registries
is often underestimated. Surveillance of population-based
cancer survival should be used by both national and local
health authorities to implement cancer control strategies
[32], to prioritise cancer control measures [33], and to
assess both the effectiveness [34, 35] and the cost-
effectiveness [36] of public health interventions.
This study investigated differences in access to care for
primary invasive liver cancer patients, excluding tumours
of the intra-hepatic biliary tract, during 10 years of epi-
demiological surveillance provided by a population-
based cancer registry that covers an area in Southern
Italy characterised by a high prevalence of HCV and by
the presence of 3 highly specialised centres for the treat-
ment HCC patients [37].
We analysed survival up to 5 years for primary invasive
liver cancer in two different subgroups of patients for
which it was possible to assess the access to care (easy
vs. poor) through implementation of a linkage algorithm
with the hospital records.
Our findings show that an easy access to care for
primary liver cancer was more frequent in patients with
Table 1 Demographic characteristics of patients with primary invasive liver neoplasm. Palermo Province Cancer Registry, 2006–2015
Primary invasive liver neoplasm (C22.0) Total (%) Sex Age at diagnosis (years)
M (%) F (%) 15–64 (%) 65–74 (%) ≥75 (%) Mean p-value
Epithelial liver tumours with defined morphologya 1259 (62.4) 860 (68.3) 399 (31.7) 351 (27.9) 524 (41.6) 384 (30.5) 69 0.0001
Malignant neoplasm with a clinical-instrumental
diagnosisb
759 (37.6) 430 (56.7) 329 (43.3) 150 (19.8) 228 (30.0) 381 (50.2) 73
Total 2018 (100) 1290 (63.9) 728 (36.1) 501 (24.8) 752 (37.3) 765 (37.9)
aEpithelial liver tumours: ICD-O-3 codes 8170–8175; 8010; 8020; 8021; 8190; 8246; 8249)
bMalignant neoplasms with a clinical-instrumental diagnosis: ICD-O-3 code 8000, behaviour code 3
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a morphologically verified tumour. These patients tend
to be younger and to have a higher probability to survive
their cancer up to 5 years than those characterised by
poor access to healthcare. Moreover, the difference in
survival between the two groups of liver cancer patients
was present in each age category, supporting the evi-
dence that the better outcome can be mainly attributable
to factors related to an easier access to healthcare ser-
vices [38]. The survival improved overtime in patients
with an easier access to care, likely to reflect a progres-
sive improvement in the effectiveness of care services
offered to primary liver cancer patients [39].
Survival for liver cancer in Palermo province during
2006–2015 was higher than the average survival in Italy
[38]. These results may support the effectiveness of
intensive follow-up conducted by a hub-and-spoke
network of centres that are specialised in the treatment
of hepatitis-related diseases [40] recruiting patients of all
ages with tumours at probably earlier stages.
The burden of liver cancer [38], the complexity and
cost of its management, which sometimes requires trans-
plantation [41], the peculiarity of the risk factors and
their control, have important public health implications,
both in terms of primary and secondary prevention
policies, and of care that should be accessible and fair all
over the world.
We have focused on hepatocellular cancer in consider-
ation of the epidemiologic shifts related to several inno-
vations: the wider use of semi-annual surveillance, that
expanded the proportion of tumours qualifying for treat-
ments of curative intent, the improved outcome from
loco-regional treatments [17], and the recent access to
innovative drugs have driven an improvement of survival
for HCC in Italy, particularly after 2009, for patients
diagnosed at an early- or intermediate- stage, whether or
not the cancer had a viral origin [5, 42–44]. Therefore,
the epidemiological scenario of HCC has evolved in
terms of both an increasing patient aging and a progres-
sive expansion of non-viral liver cancer cases, namely
“metabolic” hepatocellular carcinomas, or cryptogenetic
and multi-aetiology cases, together with the ongoing
reduction of viral cases [17]. A recent review sum-
marised evidences suggesting that several environmental
exposures - in particular to aflatoxin, air pollution,
polycyclic aromatic hydrocarbons, asbestos, chimney
sweeping occupation, and paints, heavy metals, methyl
tertiary-butyl ether, and selenium - may be associated
not only with liver cancer but also with non-alcoholic
fatty liver disease (NAFLD) [45].
The body of this evidence suggest an increasing need
for implementation of prevention strategies to target
non-viral risk factors associated with liver diseases and,
particularly, with hepatocellular carcinoma. At the same
time, beyond the classic epidemiologic surveillance com-
petencies, the role of population-based cancer registries
is crucial to produce indicators in support of the eco-
nomic impact of cancer-related costs analysis and the
planning of oncological services [46]. Cancer accounts
Fig. 2 HCC survival up to 5 years, by access to care: Palermo Province Cancer Registry, 2006–2015
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for an increasing proportion of health care expenditures
due to increasing in cancer incidence rates, improve-
ments in diagnostic procedures and treatments, and
population aging, the analysis of cancer-related costs,
starting from the evidences generated by population-
based cancer registries, has been of growing interest for
public health planners and policy makers [47]. Studies
designed to provide an economic assessment of diagnostic,
therapeutic and pathways to care for breast and colorectal
cancers [48–50] should perhaps be extended to include
liver cancer.
A limitation of this study is that the Barcelona Clinic
system routinely used by clinicians to stage HCC is not
usually available in population-based cancer registry [51].
A further limitation is related to the lack of information
for population-based cancer registries on the aetiology of
primary liver tumours (viral, non-viral), which is relevant
for clinical progression. Therefore, to better investigate
the differences in HCC survival between patients with easy
or poor access to care, as documented by our study, we
stress the need for a joint effort in HCC staging between
clinicians and tumour registries. In line with previous
studies, our findings support the importance for the
decision-making level to obtain real-world evidence on
cancer treatment outcomes from population-based cancer
registries, by linking them to regional health care utilisa-
tion databases [52, 53]. Moreover, the role of socioeco-
nomic status should also be investigated as it could affect
the relationship between survival and access to care [54].
Clinical registries play an import role in identifying
priorities to improve access to care [55–57] and clinical
outcomes [10, 58, 59] of liver cancer patients with poor
access to care. This study emphasises how population-
based cancer registries can play a supportive role in
meeting the increasing need to prioritise cancer control
measures [46].
Future studies using our approach should be per-
formed in order to confirm or refute our findings.
Conclusions
For a decade (2006–2015), liver cancer survival up to 5
years was higher for patients with easy access to care
than for those with poor access. Our experience high-
lights the importance of the evidence from population-
based cancer registries in designing effective policies for
cancer control. Our linkage algorithm, applied on a lar-
ger scale and for a longer calendar period, could provide
valuable evidence to support healthcare decision-making
in the context of the evolving epidemiology of hepatocel-
lular carcinoma.
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